• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic

Bioengineer by Bioengineer
February 23, 2023
in Chemistry
Reading Time: 4 mins read
0
Insilico Medicine advances generative AI-designed COVID-19 drug
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico’s proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

Insilico Medicine advances generative AI-designed COVID-19 drug

Credit: Insilico Medicine

Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico’s proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

ISM3312 is a highly selective small molecule inhibitor with a novel molecular structure optimized from compounds which were generated and designed by Chemistry42 based on the structure of 3CL protease. It binds to the target protein in a unique, irreversible, covalent binding mode,  potentially providing a broad spectrum of anti-coronavirus activities, excellent single agent oral bioavailability, and drug-resistant mutations.

In preclinical studies, ISM3312 significantly reduces viral load in lung tissue and decreases lung inflammation. It also demonstrated broad spectrum anti-coronavirus activities, not only for SARS-CoV-2 and its popular variants, but also for other types of coronaviruses. 

Non-clinical pharmacokinetic studies show that ISM3312 has promising oral absorbability, permeability, and bioavailability. Compared to existing 3CLpro inhibitors (e.g., Nirmatrelvir and Ensitrelvir), it retains a favorable in vivo efficacy at low doses, and its expected clinical efficacy is independent of co-administration with CYP3A and P-gp inhibitors (e.g., Ritonavir),  which is expected to further reduce the drug-drug interaction (DDI) issue and side effects.

Drug-resistant strains of COVID-19 may emerge with use of Paxlovid™ and other similar approved drugs given the highly mutable nature of coronaviruses. ISM3312 has the potential ability to overcome clinical resistance which may provide a solution to the problem of resistant strains caused by the widespread use of drugs with the same method of action in current clinical treatment.

“Insilico fully utilized its unique features in this internal COVID R&D program by leveraging AI capabilities with R&D expertise to design an innovative 3CLpro inhibitor with novel structure and molecular backbone,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “ISM3312 has significant differences and distinct advantages from existing 3CL protease inhibitors. We are committed to accelerating clinical trials through fast-tracking development policy of the treatment for COVID-19 to benefit patients worldwide.”

As a small molecule drug generated and designed by a generative chemistry AI platform, ISM3312 can be efficiently prepared with a two-step synthesis from simple commercially available starting materials, which may be suitable for chemistry manufacturing and control to ensure accessibility worldwide. Insilico will soon initiate clinical trials of ISM3312 in China to explore the tolerability, safety, and pharmacokinetic profile of the drug in humans, as well as its efficacy and safety in different subgroups of patients with COVID-19, thus providing an alternative option for health management in the post-pandemic era.

“There  remains  an urgent need for conducting well-designed clinical trials for scientific evaluation of potential COVID-19 therapies such as ISM3312,” said Sujata Rao, M.D., Senior Vice President, Head of Clinical Development at Insilico Medicine. “We are committed  to exploring  ongoing  unmet medical need to include  subgroups underrepresented in COVID-19 trials as well as in patients who may have variants that are more resistant to antiviral drugs.”

Insilico initially trained its generative AI platform on viral structures and knowledge discovered from the SARS pandemic. The company identified 3CL protease as the target in early 2020 by using the target discovery platform PandaOmics, then published its first set of novel compound structures designed using its generative chemistry platform Chemistry42 in February 2020 and filed a related patent application in April 2020.

“Generative AI is transforming every area of human development,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “The invention of ChatGPT has consumerized generative AI, however, generative AI is not new and our company has been working in the field since the publication of our first peer-reviewed papers in this space in 2016. We’re extremely happy to announce that our second small molecule therapeutic generated using generative AI is now entering human clinical trials and there is a very clear timeline to demonstrate the discovery and development cycle.” 

Insilico Medicine is an AI-driven biotech company pioneering the application of generative AI to drug discovery and development since 2014. Since 2021, Insilico has nominated 10 preclinical compound candidates discovered and designed by the generative AI platform Pharma.AI, covering the disease areas of fibrosis, oncology, and immunology. The most advanced is Insilico’s anti-fibrosis program. The Company is planning to conduct a global multi-center Phase II clinical trial for its anti-fibrosis drug which was also granted FDA orphan drug designation in February 2023.

About Insilico Medicine

Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

Website: www.insilico.com 

Contact: [email protected]



Share12Tweet8Share2ShareShareShare2

Related Posts

Rice membrane extracts lithium from brine faster and with reduced waste

Rice membrane extracts lithium from brine faster and with reduced waste

October 2, 2025
blank

Pseudokinases Drive Peptide Cyclization via Thioether Crosslinking

October 2, 2025

MIT Researchers Develop Simple Formula to Enhance Fast-Charging, Durable Batteries

October 2, 2025

Registration and Scientific Program Now Open for Upcoming Plasma Physics Conference

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    92 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    82 shares
    Share 33 Tweet 21
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Mayo Clinic Secures Up to $40 Million from ARPA-H to Advance Groundbreaking Air Safety Research

Atlas Reveals Testicular Aging Across Species

Early Onset of Neuroinflammation Observed in Individuals with Down Syndrome

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.